Literature DB >> 21123965

Mesenchymal stromal cells for graft-versus-host disease : basic aspects and clinical outcomes.

Kazuya Sato1, Katsutoshi Ozaki, Masaki Mori, Kazuo Muroi, Keiya Ozawa.   

Abstract

Mesenchymal stromal cells (MSCs) have unique characteristics such immune suppression by inhibiting T cell proliferation, tissue-repair ability and acceleration of hemopoietic stem cell engraftment. The cells are rare in bone marrow, but easily cultured under standard culture conditions. Soluble factors and cells are implicated in the MSC-mediated T cell suppression and numerous clinical trials using MSCs to prevent and treat graft-versus-host disease (GVHD) have been reported. MSCs are suggested to suppress acute GVHD without impairing graft-versus-leukemia effects and increasing systemic infections. In this review, we focus on basic aspects of MSC-mediated T cell suppression and clinical trials using MSCs for GVHD and related conditions.

Entities:  

Mesh:

Year:  2010        PMID: 21123965     DOI: 10.3960/jslrt.50.79

Source DB:  PubMed          Journal:  J Clin Exp Hematop        ISSN: 1346-4280


  30 in total

Review 1.  Immune modulation of inflammatory conditions: regulatory T cells for treatment of GvHD.

Authors:  Doreen Haase; Mireille Starke; Kia Joo Puan; Tuck Siong Lai; Olaf Rotzschke
Journal:  Immunol Res       Date:  2012-09       Impact factor: 2.829

2.  Unrelated allogeneic bone marrow-derived mesenchymal stem cells for steroid-refractory acute graft-versus-host disease: a phase I/II study.

Authors:  Kazuo Muroi; Koichi Miyamura; Kazuteru Ohashi; Makoto Murata; Tetsuya Eto; Naoki Kobayashi; Shuichi Taniguchi; Masahiro Imamura; Kiyoshi Ando; Shunichi Kato; Takehiko Mori; Takanori Teshima; Masaki Mori; Keiya Ozawa
Journal:  Int J Hematol       Date:  2013-07-17       Impact factor: 2.490

Review 3.  An experimental approach to the generation of human embryonic stem cells equivalents.

Authors:  Katarzyna Skowron; Marcin Tomsia; Piotr Czekaj
Journal:  Mol Biotechnol       Date:  2014-01       Impact factor: 2.695

4.  Steroid-Mediated Decrease in Blood Mesenchymal Stem Cells in Liver Transplant could Impact Long-Term Recovery.

Authors:  Nykia D Walker; Yasmine Mourad; Katherine Liu; Michael Buxhoeveden; Catherine Schoenberg; Jean D Eloy; Dorian J Wilson; Lloyd G Brown; Andrei Botea; Faraz Chaudhry; Steven J Greco; Nicholas M Ponzio; Nikolaos Pyrsopoulos; Baburao Koneru; Yuriy Gubenko; Pranela Rameshwar
Journal:  Stem Cell Rev Rep       Date:  2017-10       Impact factor: 5.739

Review 5.  Utility of co-transplanting mesenchymal stem cells in islet transplantation.

Authors:  Naoaki Sakata; Masafumi Goto; Gumpei Yoshimatsu; Shinichi Egawa; Michiaki Unno
Journal:  World J Gastroenterol       Date:  2011-12-21       Impact factor: 5.742

Review 6.  Stem cells for the treatment of musculoskeletal pain.

Authors:  Luminita Labusca; Florin Zugun-Eloae; Kaveh Mashayekhi
Journal:  World J Stem Cells       Date:  2015-01-26       Impact factor: 5.326

7.  Umbilical cord blood-derived mesenchymal stem cells ameliorate graft-versus-host disease following allogeneic hematopoietic stem cell transplantation through multiple immunoregulations.

Authors:  Qiu-Ling Wu; Xiao-Yun Liu; Di-Min Nie; Xia-Xia Zhu; Jun Fang; Yong You; Zhao-Dong Zhong; Ling-Hui Xia; Mei Hong
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2015-07-31

Review 8.  Cellular therapy for sickle cell disease.

Authors:  Allistair Abraham; David A Jacobsohn; Catherine M Bollard
Journal:  Cytotherapy       Date:  2016-07-14       Impact factor: 5.414

9.  Enhancing Cell therapies from the Outside In: Cell Surface Engineering Using Synthetic Nanomaterials.

Authors:  Matthias T Stephan; Darrell J Irvine
Journal:  Nano Today       Date:  2011-06-01       Impact factor: 20.722

10.  Characterization of the conditioned medium from amniotic membrane cells: prostaglandins as key effectors of its immunomodulatory activity.

Authors:  Daniele Rossi; Stefano Pianta; Marta Magatti; Peter Sedlmayr; Ornella Parolini
Journal:  PLoS One       Date:  2012-10-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.